TY  - GEN
AU  - Han,Tae H
AU  - Gopal,Ajay K
AU  - Ramchandren,Radhakrishnan
AU  - Goy,Andre
AU  - Chen,Robert
AU  - Matous,Jeffrey V
AU  - Cooper,Maureen
AU  - Grove,Laurie E
AU  - Alley,Stephen C
AU  - Lynch,Carmel M
AU  - O'Connor,Owen A
TI  - CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies
SN  - 1552-4604
PY  - 2014///0320
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Brentuximab Vedotin
KW  - Cross-Over Studies
KW  - Cytochrome P-450 CYP3A
KW  - metabolism
KW  - Cytochrome P-450 CYP3A Inhibitors
KW  - Drug Interactions
KW  - Feces
KW  - chemistry
KW  - Female
KW  - Hematologic Neoplasms
KW  - Humans
KW  - Immunoconjugates
KW  - Ketoconazole
KW  - Ki-1 Antigen
KW  - immunology
KW  - Male
KW  - Midazolam
KW  - Middle Aged
KW  - Oligopeptides
KW  - Rifampin
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/jcph.116
ER  -